
HPV vaccine cuts cancer risk for boys and men, new study shows
A large study finds the HPV vaccine halves the risk of HPV-related cancers in men; protection is strongest when vaccinated early (about 42% reduction for ages 9–14 and about 50% for ages 15–26), with catch-up vaccination up to 26 and shared clinical decision‑making for 27–45. Public health guidance emphasizes routine vaccination at ages 11–12 to prevent cancer across sexes and expand protection against multiple HPV strains.













